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Evaluation of Renal Perfusion in Hyperthyroid Cats before and after
Radioiodine Treatment
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Background: Hyperthyroidism and chronic kidney disease (CKD) are common in elderly cats. Consequently, both dis-
eases often occur concurrently. Furthermore, renal function is aﬀected by thyroid status. Because changes in renal perfusion
play an important role in functional renal changes in hyperthyroid cats, investigation of renal perfusion may provide novel
insights.
Objectives: To evaluate renal perfusion in hyperthyroid cats with contrast-enhanced ultrasound (CEUS).
Animals: A total of 42 hyperthyroid cats was included and evaluated before and 1 month after radioiodine treatment.
Methods: Prospective intrasubject clinical trial of contrast-enhanced ultrasound using a commercial contrast agent (Sono-
Vue) to evaluate renal perfusion. Time-intensity curves were created, and perfusion parameters were calculated by oﬀ-line
software. A linear mixed model was used to examine diﬀerences between pre- and post-treatment perfusion parameters.
Results: An increase in several time-related perfusion parameters was observed after radioiodine treatment, indicating a
decreased blood velocity upon resolution of the hyperthyroid state. Furthermore, a small post-treatment decrease in peak
enhancement was present in the renal medulla, suggesting a lower medullary blood volume.
Conclusions and Clinical Importance: Contrast-enhanced ultrasound indicated a higher cortical and medullary blood veloc-
ity and higher medullary blood volume in hyperthyroid cats before radioactive treatment in comparison with 1-month post-
treatment control.
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Both hyperthyroidism and renal disease are commonin elderly cats, and not surprisingly, these diseases
often occur concurrently. The prevalence of cats suﬀering
from both diseases has been reported to be approxi-
mately 14%.1 The incidence of azotemia shortly after
treatment of hyperthyroidism even reaches 40% suggest-
ing unmasking of pre-existing impaired renal function.1–3
A complex relationship exists between the thyroid glands
and the kidneys. In cats with hyperthyroidism, increased
serum thyroxine concentrations induce decreased vascu-
lar resistance as well as increased cardiac output, leading
to increased renal blood ﬂow, and subsequently an
increased glomerular ﬁltration rate (GFR).4 Treatment
of hyperthyroidism inversely results in a decrease in GFR
1 month after treatment, whereas GFR is found to be
stable between 1 and 6 months post-treatment.2,5 Impor-
tantly, predicting changes in renal function before treat-
ment of hyperthyroidism is complicated. Routine renal
variables such as serum creatinine concentration, serum
urea concentration, urine speciﬁc gravity, and proteinuria
are insensitive because they are strongly inﬂuenced by the
hyperthyroid state of the cat.4 Pretreatment measurement
of GFR shows promise in predicting post-treatment azo-
temia, but substantial overlap exists with cats that remain
nonazotemic.2,4 Therefore, an ideal test to predict post-
treatment azotemia currently is not available.
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AUC area under the curve
bpm beats per minute
CEUS contrast-enhanced ultrasound
CKD chronic kidney disease
EDTA ethylenediaminetetraacetic acid
FT fall time
GFR glomerular ﬁltration rate
mTT mean transit time
PE* peak enhancement normalized to interlobar artery
PE peak enhancement
ROI region of interest
RT rise time
sCr serum creatinine
TSH thyroid-stimulating hormone
TT4 total thyroxine
TTP time to peak
UPC urinary protein:creatinine ratio
USG urine speciﬁc gravity
WiAUC wash-in area under the curve
WiPI wash-in perfusion index
WiR wash-in rate
WoAUC wash-out area under the curve
WoR wash-out rate
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Renal blood ﬂow plays a fundamental role in the
functional renal changes present in hyperthyroid cats;
hence, evaluation of renal perfusion could provide
important new insights into renal function in hyperthy-
roid cats. However, performing an accurate, noninva-
sive measurement of renal perfusion is challenging.
Contrast-enhanced computed tomography, magnetic
resonance imaging, and renal scintigraphy can provide
information about macroperfusion.6–8 However, their
use in clinical practice is limited by equipment availabil-
ity, involvement of ionizing radiation, use of nephro-
toxic contrast agents, or some combination of these.6–8
Contrast-enhanced ultrasound is a functional ultra-
sound modality that allows assessment of both macro-
and microperfusion by use of an IV-administered
contrast agent. The contrast agent consists of gas-ﬁlled
microbubbles stabilized by an outer phospholipid shell
that is approximately the size of red blood cells. Conse-
quently, they do not cross the endothelium and act as
blood pool agents. Major advantages associated with
CEUS are its excellent safety proﬁle allowing use in
geriatric patients and patients suﬀering from renal dis-
ease, noninvasive nature, absence of ionizing radiation,
and relatively short imaging times.9 In human medicine,
CEUS has been shown to be useful in the diagnosis of
patients with allograft rejection, diabetic nephropathy,
and chronic renal disease.10–14 In dogs, CEUS was
capable of detecting perfusion changes in iatrogenically
induced ischemic renal disease and iatrogenic
hypercortisolism.15,16 Promising results also have been
obtained in cats, in which, renal vasoconstriction
induced by angiotensin II infusion could be detected by
CEUS but not by renal scintigraphy.17
The objective of our study was to evaluate renal perfu-
sion with CEUS in hyperthyroid cats before and after
radioiodine treatment. The hypothesis was that higher
renal perfusion, both higher blood velocity and higher
blood volume, would be present before radioiodine treat-
ment compared to the 1-month post-treatment control.
Materials and Methods
Fifty-one client-owned hyperthyroid cats presented for radioio-
dine treatment at the Faculty of Veterinary Medicine of Ghent
University (Belgium) were included in the study with the permis-
sion of the local ethical committee of Ghent University (EC 2015/
67). Owners signed an informed consent form before inclusion.
Inclusion criteria were a diagnosis of hyperthyroidism based on
clinical signs, increased serum total thyroxine concentration (TT4)
based on the references range of 10–30 nmol/L, and increased
pertechnetate uptake in 1 or both thyroid glands on scintigraphic
scan. Cats with concurrent systemic disease (including pre-existing
overt renal disease) or with clinically relevant cardiac disease (de-
ﬁned as severe left atrial dilatation, signs of congestive heart fail-
ure, or clinically relevant arrhythmias) were excluded. Antithyroid
medication (methimazole, carbimazole) or iodine-restricted dieta
was discontinued at least 10 days before radioiodine treatment.
Cats maintained their original diet throughout the study period.
Cats receiving a homemade diet or diets based on raw meat were
excluded.
The cats were evaluated on the day of radioiodine treatment
and 1 month after treatment (mean, 32 days after treatment;
range, 25–43 days). Pretreatment evaluation included a thorough
physical examination, standard 2-view thoracic radiographs (lat-
eral and ventrodorsal projections), abdominal ultrasound examina-
tion, CEUS of the kidneys, and cardiac ultrasound examination.
Post-treatment evaluation included physical examination, CEUS
of the kidneys, and cardiac ultrasound examination. A CBC,
serum biochemistry proﬁle including serum TT4, and complete uri-
nalysis (urine speciﬁc gravity, urinary pH, urinary protein: crea-
tinine ratio, sediment examination,18 and bacterial culture) were
performed on both occasions. On both occasions, systolic blood
pressure was measured by Doppler ultrasonic technique, following
the consensus statement of the American College of Veterinary
Internal Medicine.19 Physical examination and blood pressure
measurement were performed before the other examinations and
after an acclimatization period.
In 10 of 42 cats, GFR was measured using a plasma exogenous
creatinine clearance test. This test was performed 1 day before
radioiodine treatment and repeated 1 day before the post-treat-
ment examination. A limited sampling strategy, minimally impact-
ing the reliability of the GFR estimate, was used, as previously
described.20 Brieﬂy, 40 mg/kg creatinine was administered IV and
blood samples were taken in EDTA tubes before and 5, 30, 60,
120, 180, 360, and 600 minutes after injection. The borderline
GFR cutoﬀ value was deﬁned as 1.7 mL/min/kg, the lower GFR
cutoﬀ value as 1.2 mL/min/kg.20
The cats were treated with an individually adapted dose of
radioiodine (131-I) injected IV, after the previously described
examinations. The dose was based on the severity of the clinical
signs, serum TT4, and thyroid-to-salivary gland ratio as deter-
mined on the pertechnetate scan, as described previously.21 The
mean dose administered was 146,99 MBq (range, 67,71–
455,10 MBq).
CEUS Procedure
A 22-gauge indwelling catheter was placed in the cephalic vein.
Anesthesia was induced with a bolus of propofol,b 3.5–7.7 mg/kg
IV given to eﬀect, and maintained with 0–3 additional boluses as
necessary to cover the total duration of the study lasting approxi-
mately 15 minutes. Anesthesia was used for both the pre- and
post-treatment CEUS examination.
The hair was clipped over the ventrolateral aspect of the abdo-
men, and coupling gel was applied to the skin. The ultrasound
examinations were performed with the cat in dorsal recumbency.
The kidney of interest was centered on the screen and was imaged
in a longitudinal plane using dual-screen (simultaneous display of
conventional B-mode and contrast-mode images). The transducer
was manually positioned during each imaging procedure and was
maintained at the same position during the CEUS examination.
The contrast agent,c 0.05 mL/kg, was injected IV (bolus injec-
tion over  3 s) followed by injection of a 1.5 mL saline bolus. A
3-way stopcock was used to avoid any delay between the injection
of contrast agent and saline. The same person performed the injec-
tion in a standardized way. Three injections of contrast were per-
formed: 2 for the left kidney and 1 for the right kidney. The ﬁrst
injection was not used for further analysis because it results in
lower enhancement compared to subsequent injections.22 Between
subsequent injections, to avoid artifacts, remnant microbubbles
were completely destroyed by setting the acoustic power at the
highest level and scanning the caudal aspect of the abdominal
aorta for approximately 2 minutes.
All examinations were performed with a linear transducer of
12–5 MHz on a dedicated machined with contrast-speciﬁc soft-
ware. Basic technical variables were a single focus placed under
the kidney, persistency oﬀ, mechanical index 0.09, high dynamic
range setting (C50), timer started at the beginning of the injection,
and gain 85% (corresponding to a nearly dark/anechoic image
Renal Perfusion Evaluation in Hyperthyroid Cats 1659
before contrast administration). The settings were repeated during
each injection. All studies were digitally registered as a movie clip
at a rate of 9 frames per second, for 90 seconds.
The clips were exported in DICOM format and analyzed oﬀ-
line by specialized computer softwaree for objective quantitative
analysis. Six regions-of-interest (ROIs) were manually drawn: 3 in
the renal cortex, 2 in the renal medulla, and 1 on an interlobar
artery. The ROIs were similar in size and drawn at the same depth
for every region (Fig 1). For every ROI, the software determined
mean pixel intensity as a function of time and created a time-
intensity curve. Time-intensity curves were analyzed for peak
enhancement (PE), wash-in area under the curve (WiAUC), rise
time (RT), mean transit time (mTT), time to peak (TTP), wash-in
rate (WiR), wash-in perfusion index (WiPI; WiAUC/RT), wash-
out area under the curve (WoAUC), total area under the curve
(AUC), fall time (FT), and wash-out rate (WoR). The PE corre-
sponds to the maximum contrast medium signal intensity. The
WiAUC is calculated as the sum of all amplitudes inside the range
from the beginning of the curve up to the TTP. Similarly,
WoAUC corresponds to the sum of all amplitudes inside the range
from the TTP to the end of the descending curve. The other
parameters, that is, RT, mTT, TTP, WiR, WiPI, FT, and WoR,
are related to blood velocity. The WiR and WoR represent the
maximum and minimum slopes of the time-intensity curves. The
RT corresponds to the time interval between the ﬁrst arrival of
contrast and the time of peak intensity. The FT, in contrast, is the
duration of contrast wash-out. Mean transit time is the mean
duration of complete contrast medium perfusion. The values for
the 3 ROIs in the renal cortex and 2 ROIs in the renal medulla
were averaged. Peak enhancement, for the cortex and medulla,
was normalized to the values obtained for the interlobar artery
(PE*).
Statistical Analysis
Analysesf were based on a linear mixed model with cat and kid-
ney nested in cat as random eﬀects and treatment (pre/postra-
dioiodine treatment) as a categorical ﬁxed eﬀect. Analyses were
performed separately for the renal cortex and medulla. Correla-
tions between perfusion parameters and heart rate, blood pressure,
serum TT4, sCr, and GFR were calculated for the renal cortex
and medulla using Spearman correlation coeﬃcients (q). A diﬀer-
ence was considered statistically signiﬁcant if P < 0.05.
Results
In total, 9 cats were excluded from the study: 4 cats
because of additional pathology (suspected pulmonary
neoplasia, n = 1; intestinal lymphoma, n = 1; severe
cardiomegaly and left atrium dilatation, n = 1; second-
degree atrioventricular block, n = 1), 4 cats because of
aggressive behavior, and 1 cat was lost for follow-up.
For the 42 remaining cats, no clinically relevant abnor-
malities were noted on thoracic radiographs or abdomi-
nal ultrasound examination. Echocardiographic changes
were compatible with hyperthyroidism (left ventricular
hypertrophy, mild-to-moderate left atrial dilatation) and
improved after treatment of hyperthyroidism in most
cases.
Breed distribution consisted of 40 domestic short- or
long-haired cats, 1 British Shorthair, and 1 Chartreux.
Twenty-three cats were female neutered, and 19 were
male neutered. The median age at time of inclusion was
12 years 9 months (range, 7 years 5 months to 16 years
7 months).
Of the 42 cats included, 27 (64%) had post-treatment
serum TT4 within the normal reference interval, and 15
(36%) has serum TT4 value below normal. None had
serum TT4 above the normal reference interval at
1 month after radioiodine treatment. Two cats (4.8%)
developed post-treatment azotemia, 1 of them had
serum TT4 below the reference range 1-month post-
treatment. Additionally, 2 cats with normal sCr had
decreased post-treatment GFR. An overview of the
baseline characteristics of the cats, before and after
radioiodine treatment, is provided in Table 1.
Both kidneys had normal appearance on B-mode
ultrasonography in 27 cats, including 1 of the 2 cats
that developed post-treatment azotemia. Two cats (5%)
had a unilateral small kidney (<3 cm), with subjectively
decreased corticomedullary deﬁnition, 1 of these devel-
oped post-treatment azotemia, whereas the other did
not. Three (7%) other cats had mildly decreased corti-
comedullary deﬁnition in normal-sized kidneys. Three
cats (7%) had mildly irregular renal outlines, 5 (12%)
had segmental cortical lesions, and 4 (10%) had small
Fig 1. Contrast-enhanced ultrasound image of the left kidney of
a cat illustrating the position of the regions-of-interest in the renal
cortex (yellow ____), renal medulla (green ), and interlobar
artery (blue +++). The image was obtained at peak cortical
enhancement (10 seconds after contrast injection).
Table 1. Clinical variables before and 1 month after
radioiodine treatment provided as mean  standard
deviation (bpm beats per minute; TT4 total thyroxine;
USG urine speciﬁc gravity; UPC urinary protein: crea-
tinine ratio; GFR glomerular ﬁltration rate)
Variables Pretreatment
Post-
treatment
P-
value
Body weight (kg) 3.8  0.7 4.1  0.7 <0.001
Heart rate (bpm) 209.4  27.2 169.7  28.5 <0.001
Blood pressure
(mmHg)
161.2  29.8 162.7  31.8 0.793
TT4 114.6  27.9 13.0  27.9 <0.001
sCr (lmol/L) 65.3  26.6 109.6  26.6 <0.001
Serum urea (mmol/L) 8.7  3.2 10.4  3.2 <0.001
USG 1.044  0.006 1.037  0.006 <0.001
UPC 0.71  0.32 0.23  0.32 <0.001
GFR (mL/kg/min) 3.6  1.9 2.1  1.9 0.003
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cystic lesions, none of these cats developed post-treat-
ment azotemia. One cat (2%), without post-treatment
azotemia, had mild bilateral pyelectasia without signs of
obstruction, which improved post-treatment. Eight cats
(19%) had bilateral hyperechoic renal cortices, and
all of them were castrated males, suggesting fat
inﬁltration.23
No clinically relevant adverse eﬀects of the sono-
graphic contrast material were noted. However, 1 cat
experienced mild and transient tachypnea after the ﬁrst
injection of contrast agent during the pretreatment
evaluation, which resolved spontaneously within
10 minutes.
Several perfusion parameters showed signiﬁcant
changes between pre- and post-treatment values. A
comparison between the perfusion parameters before
and after radioiodine treatment is provided in Table 2.
Moreover, representative time-intensity curves are pro-
vided in Figure 2.
The RT (P < 0.001), mTT (P = 0.011), TTP
(P < 0.001), and FT (P < 0.001) for the renal cortex
increased signiﬁcantly post-treatment. In parallel, the
WiR (P = 0.008) and WoR (P = 0.004) decreased. A
post-treatment increase also was seen for the WiAUC
(P < 0.001), WoAUC (P < 0.001), and total AUC
(P < 0.001) for the renal cortex. Similarly, for the renal
medulla, RT (P = 0.001) and TTP (P < 0.001) increased
post-treatment, whereas WiR (P = 0.004) decreased.
Moreover, a signiﬁcant post-treatment decrease in
normalized PE (PE*; P = 0.044) was observed for the
medulla.
Signiﬁcant negative correlations were present between
heart rate and RT in the cortex (q = 0.46; P < 0.001),
and TTP for both cortex (q = 0.42; P = 0.001) and
medulla (q = 0.39; P = 0.003), meaning that shorter
TTP and RT, and thus higher renal blood velocity,
were present as heart rate increased. Similarly, signiﬁ-
cant negative correlations were found between serum
TT4 and cortical RT (q = 0.60; P < 0.001), TTP
(q = 0.59; P < 0.001) and FT (q = 0.57; P < 0.001),
and medullary TTP (q = 0.48; P < 0.001). Moreover,
a positive correlation was found between sCr and corti-
cal (q = 0.68; P < 0.001) and medullary (q = 0.41;
P = 0.001) TTP, and cortical FT (q = 0.52; P < 0.001).
Negative correlations were found between GFR and
cortical TTP (q = 0.51; P = 0.021), cortical RT
(q = 0.53; P = 0.002), cortical FT (q = 0.50;
P = 0.024), and medullary RT (q = 0.62; P = 0.004)
and FT (q = 0.68; P = 0.001).
Signiﬁcant correlations also were present between
heart rate and sCr (q = 0.48; P < 0.001), heart rate
and GFR (q = 0.47; P = 0.042), heart rate and serum
TT4 (q = 0.59; P < 0.001), serum TT4 and sCr
(q = 0.71; P < 0.001), and serum TT4 and GFR
(q = 0.61; P = 0.004), complicating the interpretation.
There was no signiﬁcant diﬀerence in pre- and post-
treatment blood pressure.
Discussion
Several studies have investigated routine urine and
serum renal markers and GFR in hyperthyroid cats
before and after treatment.2,3,5,24–27 Ours is the ﬁrst
study to focus on renal perfusion. Evaluation of renal
blood ﬂow is of major interest because the changes in
perfusion are known to cause changes in GFR and may
therefore precede the eﬀect on GFR.4
Contrast-enhanced ultrasound was able to detect sig-
niﬁcant changes in renal blood ﬂow before and after
radioiodine treatment. A faster inﬂow of contrast agent,
reﬂected by lower RT and TTP, was present during the
hyperthyroid state. Similarly, a faster outﬂow (FT) was
Table 2. Mean  standard deviation values of renal
perfusion parameters in hyperthyroid cats before and
1 month after radioiodine treatment.
Variable, by
location Pretreatment Post-treatment P-value
Renal cortex
PE 2193.27  958.18 2146.47  958.18 0.771
PE* 20.09  9.59 19.06  9.59 0.557
WiAUC 3566.26  1751.87 4864.32  1751.87 <0.001
RT 2.79  0.66 3.79  0.66 <0.001
mTT 24.36  10.37 28.73  10.37 0.011
TTP 7.83  1.43 9.91  1.43 <0.001
WiR 1119.38  553.84 793.75  553.84 0.008
WiPI 1342.53  584.95 1317.72  584.95 0.801
WoAUC 4830.39  2389.00 6767.46  2389.00 <0.001
AUC 8396.54  4124.15 11632.00  4124.15 <0.001
FT 3.87  1.10 5.46  1.10 <0.001
WoR 755.90  407.57 501.47  407.57 0.004
Renal medulla
PE 308.93  162.93 270.59  165.39 0.093
PE* 3.01  1.68 2.37  1.68 0.044
WiAUC 2530.39  1312.61 2512.68  1334.13 0.935
RT 14.01  4.28 16.25  4.41 0.001
mTT 68.36  70.83 87.84  72.52 0.196
TTP 24.58  4.93 30.99  4.99 <0.001
WiR 36.90  24.82 27.40  25.15 0.004
WiPI 194.04  101.36 168.53  102.85 0.075
WoAUC 4403.78  2352.51 3974.35  2403.64 0.259
AUC 6949.01  3629.28 6442.36  3708.28 0.387
FT 25.54  8.55 26.80  8.75 0.386
WoR 18.98  14.65 15.28  14.91 0.072
Fig 2. Representative time-intensity curves for the renal cortex
of a hyperthyroid cat before and 1 month after radioiodine
treatment.
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present. Consequently, the time of duration of con-
trast enhancement (mTT) was shorter. The WiR and
WoR, representing the slope of, respectively, the
inﬂow and outﬂow phases of the time-intensity curve,
were higher in the pretreatment phase. The combina-
tion of these ﬁndings indicates a higher velocity of
renal blood ﬂow in hyperthyroid cats, which decreases
signiﬁcantly 1 month after 131-I treatment. Similar
changes were present for the renal medulla. The
changes in CEUS parameters can in part be attribu-
ted to the decreased systemic vascular resistance that
is present in hyperthyroidism. Thyroid hormones
induce increased nitric oxide concentrations in the
renal cortex and medulla, resulting in vasodilatation.
Additionally, an increased number of beta-adrenergic
receptors is present in the renal cortex during the
hyperthyroid state.4 Secondly, the ultrasound contrast
agent is injected IV and hence travels in the systemic
circulation before reaching the kidney. Therefore, the
higher heart rate and cardiac output in hyperthyroid
cats will have reinforced the eﬀects on renal blood
velocity. This also is reﬂected by the moderate nega-
tive correlations between heart rate and several time-
based perfusion parameters.
The AUC of the renal cortex signiﬁcantly increased
after radioiodine treatment. The AUC is inﬂuenced by
both the height of the time-intensity curve (intensity,
represented by the PE) and the width of the curve
(time, represented by several time-based parameters,
most importantly mTT). No signiﬁcant changes were
observed in PE after radioiodine treatment. Therefore,
the change in AUC can be attributed to the longer
duration of contrast enhancement after radioiodine
treatment.
Although most of the previously mentioned data were
obtained in the renal cortex, little is known about the
microvascular alterations accompanying hyperthy-
roidism in the renal medulla. Our study showed a small,
but signiﬁcant decrease in normalized PE (PE*) for the
renal medulla after radioiodine treatment indicating a
larger blood volume in the renal medulla during the
hyperthyroid state. The hyperthyroid state induces
increased renal blood ﬂow, resulting from a combina-
tion of increased cardiac output, decreased vascular
resistance, overall increased blood volume, and upregu-
lation of beta-adrenergic receptors in the renal
cortex.4,28 A higher estimated renal blood ﬂow in hyper-
thyroid cats has been described previously.29 In that
study, total renal blood ﬂow was measured using a
radionuclide based technique (131-I ortho-iodo-hippu-
rate). Nevertheless, no signiﬁcant changes were
observed in PE for the renal cortex in our study,
although they were expected. This ﬁnding is most likely
caused by the high variability and consequently broad
95% conﬁdence intervals for this parameter.30,31 The
intensity measured on CEUS images, and thus the PE,
is strongly inﬂuenced by several factors. Uncontrollable
patient-related factors such as ﬁltration by the lungs
and phagocytosis by the reticuloendothelial system will
inﬂuence the ﬁnal microbubble concentration in the
renal parenchyma.32,33
Only, 4.8% of the cats in our study developed post-
treatment azotemia, which is considerably lower than
the 17–39% reported in literature.1,2,25,26 The percent-
age of cats having serum TT4 below the reference inter-
val 1 month after radioiodine treatment (36%) was
similar to values reported in literature (24–51%).24,34,35
Iatrogenic hypothyroidism is well known to contribute
to the development of renal dysfunction.35 On the other
hand, CKD can induce euthyroid sick syndrome with
suppression of serum TT4. Measurement of thyroid-sti-
mulating hormone (TSH) allows diﬀerentiation between
iatrogenic hypothyroidism and euthyroid sick syn-
drome. The combination of low TT4 and high TSH is
consistent with iatrogenic hypothyroidism.4,28 However,
TSH concentration also is inﬂuenced by radioiodine
treatment, and TSH concentration is reported to be
within normal reference interval 3 months after radioio-
dine treatment.35 Thyroid stimulating hormone was not
measured in our study.
Because of the low number of cats developing CKD
after radioiodine treatment in our study, it was not pos-
sible to assess the predictive value of CEUS for the
development of post-treatment azotemia. Longer fol-
low-up might have allowed identiﬁcation of additional
cats developing CKD, but signiﬁcant changes in renal
function are reported to occur within 4 weeks after
treatment and not thereafter.2,5
Contrast-enhanced ultrasound is a short, nonpainful
procedure and thus sedation or anesthesia usually is not
necessary. However, to perform accurate quantiﬁcation
afterward, it is mandatory that the animals remain
immobile during the acquisition of the CEUS clip. Tak-
ing into account that hyperthyroid cats often are hyper-
active, stress intolerant and even aggressive, anesthesia
may be required in some hyperthyroid cats. Propofol
anesthesia may inﬂuence CEUS parameters, causing a
delay in TTP and a slower wash-in of contrast agent.36
Therefore, to compare the perfusion parameters, it was
necessary to use anesthesia in all cats, both before and
after radioiodine treatment. In our study, heart rate,
blood pressure, and cardiac output were not evaluated
during the period of anesthesia. Therefore, the hemody-
namic inﬂuence of the anesthetic agent could not be
evaluated.
In conclusion, CEUS allowed assessment of renal
perfusion in hyperthyroid cats before and after radioio-
dine treatment. A signiﬁcant decrease in both cortical
and medullary blood velocity was noted 1 month after
radioiodine treatment. However, no signiﬁcant decrease
in blood volume could be detected in the renal cortex,
whereas a post-treatment decrease in normalized PE
was observed in the renal medulla.
Footnotes
a Hill’s Prescription Diet Y/D, Hill’s Pet Nutrition, Topeka, Kan-
sas
b Propovet, Abbott Laboratories, Chicago, Illinois
c SonoVue, Bracco, Milan, Italy
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d iU22, Philips, Amsterdam, The Netherlands
e VueBox, Bracco Suisse SA, Geneva, Switzerland
f SAS version 9.4, SAS Institute Inc, Cary, North Carolina
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